Please login to the form below

Not currently logged in
Email:
Password:

Bayer moves vilaprisan into phase III trials for uterine fibroids

ASTEROID study will investigate safety and efficacy of the novel drug

Bayer

Bayer is beginning late-stage trials of vilaprisan, its novel oral, selective progesterone receptor modulator (SPRM) treatment for women with uterine fibroids.

The three-year, phase III ASTEROID study will investigate the efficacy and safety of 2mg of vilaprisan in patients with symptomatic uterine fibroids, and aims to recruit more than 3,600 patients in 900 centres across 40 countries.

Uterine fibroids are the most common benign gynecological tumors, with approximately 5-10% of women requiring treatment for the disease.

Efficacy measures will be assessed within the trial programme including the effect on heavy menstrual bleeding, reduction in fibroid size and improvement in quality of life.

Dr Joerg Moeller, member of the executive committee of Bayer AG’s pharmaceutical division and head of development, said the work would build on a phase II study of vilaprisan that had delivered “promising results”.

“It is our ambitious goal that our research efforts in this field result in a medical therapy that control symptoms and thereby significantly improves the quality of life for women with uterine fibroids,” he added.

Meanwhile, Allergan and Gedeon Richter plan to file their uterine fibroid drug ulipristal acetate in the US by the end of the year and Astellas is also busy in this area, have acquired Ogeda and its phase IIa candidate Fezolinetant.

Article by
Gemma Jones

7th July 2017

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
#DemandDiversity: Black history in clinical trials: It's more than just Tuskegee [Infographic]
Take a look at this infographic showing some of the most notorious clinical trials and medical research in history....

Infographics